Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 16, 2001
Chloroquine - some open questions on its antimalarial mode of action and resistanceHagai Ginsburg, Miriam KrugliakExperimental Parasitology|May 19, 2006
The evolution of the new permeability pathways in Plasmodium falciparum--infected erythrocytes--a kinetic analysisMiriam Krugliak, Hagai GinsburgMolecular and Biochemical Parasitology|January 30, 2002
Intraerythrocytic Plasmodium falciparum utilizes only a fraction of the amino acids derived from the digestion of host cell cytosol for the biosynthesis of its proteinsMiriam Krugliak, Jianmin Zhang, Hagai GinsburgInternational Journal of Molecular Sciences|September 28, 2023
Viroporins of Mpox VirusKingshuk Basu, Miriam Krugliak, Isaiah T ArkinMolecular and Biochemical Parasitology|May 26, 2007
Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugsJan M Woynarowski, Miriam Krugliak, Hagai GinsburgBiochemical Pharmacology|November 22, 2005
Arylpiperazines displaying preferential potency against chloroquine-resistant strains of the malaria parasite Plasmodium falciparumCarrie-Anne Molyneaux, Miriam Krugliak, Hagai Ginsburg, et al.Plos One|October 25, 2011
Promiscuous binding in a selective protein: the bacterial Na+/H+ antiporterRaphael Alhadeff, Assaf Ganoth, Miriam Krugliak, et al.Viruses|April 3, 2021
Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug RepurposingPrabhat Pratap Singh Tomar, Miriam Krugliak, Isaiah T ArkinJournal of the American Chemical Society|May 4, 2011
How do aminoadamantanes block the influenza M2 channel, and how does resistance develop?Hadas Leonov, Peleg Astrahan, Miriam Krugliak, et al.Pharmaceuticals (Basel, Switzerland)|July 2, 2021
Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug LibraryPrabhat Pratap Singh Tomar, Miriam Krugliak, Isaiah T ArkinPageof 3